It also upregulated the transcription factor peroxisome proliferator-activated receptor gamma (PPARγ) and downregulated lipogenic enzymes (like fatty acid synthase and HMG-CoA reductase) in rodent models, thereby improving dyslipidemia and possibly adipose tissue inflammation [81]. The gene discussed is FASN; the disease is metabolic syndrome.